marketing-medtech

**Country:** Germany (Berlin)
**Founder:** Eva-Maria Meijnen (Co-CEO) & Dr. Valerie Kirchberger (Co-CEO) — Co-Founders & Co-CEOs
**Background:** clinician | verified: True — The "clinician" claim is accurate for ONE of the two named co-CEOs, not both. Dr. Valerie Kirchberger (Co-Founder & Co-CEO) IS a clinician: she trained as a paediatrician, received her doctorate (Dr.) in 2009, and practiced clinically at the Children's Hospital of Ludwig Maximilian University in Munich (2009-2011) and in the Department of Paediatric and Adolescent Medicine at Charité - Universitätsmedizin Berlin (2011-2016). She also holds a Master's in Public Health and later worked in value-based healthcare/PROMs (Charité Strategy Dept., then Chief Medical Officer at Heartbeat Medical) before co-founding Evela Health in early 2024. By contrast, the OTHER co-CEO, Eva-Maria Meijnen, is NOT a clinician: she is an industrial engineer by training (University of Karlsruhe) with a corporate/business-operations background (prior exit at dental startup PlusDental). Evela Health also has a third co-founder, Dr. Cornelius Remschmidt. So "clinician" describes Kirchberger but is incorrect if applied to Meijnen.
**Stage / fundraise:** Pre-seed / early seed, founded early 2024 (~2.5 years old) / ~EUR 2.6M raised to date. EUR 600K pre-seed (May 2025, BetterVentures + angels), then a EUR 2M round closed 17 Sept 2025 (Impact Shakers, BetterVentures, angels) including EUR 1.2M non-dilutive grant from IBB Berlin. Funds earmarked for tech/AI hiring, sales and platform development — i.e. building the team in-house. Likely to raise a priced seed next, but no announced active round as of the source dates.
**Regulatory trigger:** No concrete regulatory trigger found. Product is positioned as "evidence-based" but is NOT presented as a regulated medical device; no mention of MDR, CE marking, IEC 62304, or DiGA reimbursement in any source. Roadmap to add "wearable health data and AI-driven analysis" could push toward SaMD/MDR territory in future, but this is speculative, not stated. Existing reimbursement-adjacent signal: a contract with insurer HanseMerkur and a B2B2C corporate-benefit distribution model.
**Email:** info@evela.health (confidence high) — info@evela.health is the published company contact address on the official Evela Health imprint page (https://www.evela.health/en/imprint). This is a verified, published generic inbox — not a personal founder address. The founder personal-email pattern (e.g. valerie@ / eva-maria@ / eva@evela.health) is NOT confirmed by any source and is therefore not asserted.
**LinkedIn:** https://www.linkedin.com/in/valerie-kirchberger/ ; https://www.linkedin.com/in/eva-maria-meijnen-5420911a/ ; company: https://de.linkedin.com/company/evela-health-gmbh **Website:** https://www.evela.health
**Score:** 5 -> Tier C
**Hook:** Limited authentic hook for OmDev. Honest angle if pursued: Evela just raised EUR 2M (Sept 2025) partly to add wearable + AI-driven analytics; as that wearable/AI layer turns "evidence-based wellness" into something closer to SaMD, the MDR/IEC 62304 burden lands on their existing small tech team. OmDev could offer burst senior-dev capacity plus a SOUP register and requirements-to-code-to-test traceability feeding an MDR technical file — without them having to scale headcount. Caveat: they already have a capable CTO and are explicitly hiring tech in-house, so this is a capacity/compliance-augmentation pitch, not a "be your tech team" pitch. Founders are clinical/operator, not finance.

---

## Founder & background
Co-led by **Eva-Maria Meijnen** (Co-CEO, industrial engineer & med-tech entrepreneur) and **Dr. Valerie Kirchberger** (Co-CEO, physician + Master of Public Health; ex-Charité, value-based-care / patient-reported-outcomes specialist). A third founder, **PD Dr. Cornelius Remschmidt** (CSO, ex-CMO Data4Life), rounds out the science side. This is a **clinical/operator** founding team — **not** the finance/insurance profile OmDev prioritizes. ([about-us](https://www.evela.health/en/about-us), [Femtech Insider](https://femtechinsider.com/evela-health-completes-e2m-funding-round-to-transform-menopause-care-in-german-speaking-markets/))

## Funding & momentum
Founded early 2024. Raised **EUR 600K pre-seed (May 2025**, BetterVentures + angels), then a **EUR 2M round on 17 Sept 2025** (Impact Shakers, BetterVentures, angels) including **EUR 1.2M non-dilutive from IBB Berlin** — ~EUR 2.6M total. Money is earmarked for **in-house tech/AI hiring**, sales and platform development. Genuine early-stage momentum, but the capital is explicitly going toward building the team internally. ([startbase](https://www.startbase.com/news/evela-health-mit-600000-euro-pre-seed-erfolgreich/), [why.berlin](https://why.berlin/n/berlins-evela-health-raises-eur2m-for-menopause-care/))

## Product & regulatory
B2B2C **digital menopause platform** sold to employers as a corporate benefit for women 40+: knowledge base across ~10 life dimensions, specialist consultations, webinars; roadmap adds **wearable data + AI analysis**. Positioned as "evidence-based" but **not** a regulated medical device — **no MDR, CE, IEC 62304 or DiGA** mention in any source. An insurer contract (HanseMerkur) exists. Regulatory trigger is **speculative** (AI/wearable layer could later cross into SaMD). ([Femtech Insider](https://femtechinsider.com/evela-health-completes-e2m-funding-round-to-transform-menopause-care-in-german-speaking-markets/), [about-us](https://www.evela.health/en/about-us))

## Pain & buying signals
**Weak fit — Tier C.** Decisive negative: Evela **already has a CTO** (Emilio De Lazzari, ~20 yrs product/web, ex-Finleap, ex-sennder) plus a CSO, and the Sept-2025 raise is **explicitly funding in-house tech/AI hiring** — the opposite of OmDev's outsourced-team thesis. No acute MDR/IEC 62304 milestone to anchor the compliance engine, and founders aren't finance/insurance. ([join.com CTO listing](https://join.com/companies/evela/14921508-chief-technology-officer), [about-us](https://www.evela.health/en/about-us))

**Why OmDev fits (qualified):** Only a *capacity + compliance-augmentation* pitch is honest here: if/when the wearable+AI layer turns the product into SaMD, OmDev can supply burst senior-dev capacity plus a SOUP register and requirements-to-code-to-test traceability feeding an MDR technical file, sparing them a headcount ramp. But with a strong existing CTO actively building in-house, the core OmDev value prop (be your tech team + dedicated CTO, ~3x cheaper than in-house) does not land — deprioritize.

---
**Sources:** https://femtechinsider.com/evela-health-completes-e2m-funding-round-to-transform-menopause-care-in-german-speaking-markets/ · https://www.evela.health/en/about-us · https://www.evela.health/en/imprint · https://www.startbase.com/news/evela-health-mit-600000-euro-pre-seed-erfolgreich/ · https://why.berlin/n/berlins-evela-health-raises-eur2m-for-menopause-care/ · https://join.com/companies/evela/14921508-chief-technology-officer · https://de.linkedin.com/company/evela-health-gmbh · https://www.linkedin.com/in/valerie-kirchberger/ · https://www.linkedin.com/in/eva-maria-meijnen-5420911a/ · https://www.everythingstartups.com/article/femtech-startups-that-got-funded-in-september-2025